Indegene Ltd. IPO

We provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the ... sales and marketing of their products. We combine over two decades of healthcare domain expertise and our technology platforms to provide solutions that assist life science companies in clinical trials, support their regulatory and safety operations, aid in the launch of their products in the market and drive sales and marketing through the life cycle of their products. Our portfolio of solutions covers all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. As of December 31, 2023, we had 65 active clients whom we cater to from six operation hubs and 17 offices located across North America, Europe and Asia. Read more

Our Company was incorporated as ‘Indegene Lifesystems Private Limited’ at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & ... Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to ‘Indegene Private Limited’ and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to ‘Indegene Limited’ and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.

The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at ?138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or ?95.4 trillion (US$1.2 trillion) of such sales. Combined ... sales of biopharmaceutical companies and medical devices companies are estimated to reach ?163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at ?12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach ?15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales. Read more